Skip to main content

Gefitinib missed noninferiority endpoint vs. erlotinib in lung cancer trial

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Gefitinib missed noninferiority endpoint vs. erlotinib in lung cancer trial

User login

Username

Password

Reset your password

Type	Lead	score